Literature DB >> 15884091

The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.

Melinda E Sanders1, Peggy A Schuyler, William D Dupont, David L Page.   

Abstract

BACKGROUND: Opportunities to study the natural history of ductal carcinoma in situ (DCIS) are rare. A few studies of incompletely excised lesions in the premammographic era now recognized as DCIS have provided critical insights into its proclivity for local recurrence in the original site. At the time the biopsies in the current study were originally examined, small DCIS was not diagnosed and, by default, these women were treated by biopsy only.
METHODS: The authors report the latest results from a follow-up study, which was published originally in 1982, of 28 women with low-grade DCIS who were treated by biopsy only. These women were from a large, prospectively identified, completely characterized cohort.
RESULTS: Eleven of 28 women developed invasive breast carcinoma (IBC), all in the same breast and quadrant from which their low-grade DCIS biopsy was taken. Seven IBCs were diagnosed within 10 years of the DCIS biopsy, 1 was diagnosed within 12 years of the DCIS biopsy, and the remaining 3 IBCs were diagnosed over 23-42 years. Five of these women, including 1 woman who developed IBC 29 years after her DCIS biopsy, developed distant metastasis, which resulted in death 1-7 years after the diagnosis of IBC.
CONCLUSIONS: The natural history of low-grade DCIS can extend greater than 4 decades, with IBC developing at the same site as the previous DCIS in the majority of women. This natural history differs markedly from that of patients with high-grade DCIS and from the outcome of patients with any completely delimited DCIS excised to negative margins. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2005        PMID: 15884091     DOI: 10.1002/cncr.21069

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  135 in total

1.  Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop.

Authors:  Ann H Partridge; Joann G Elmore; Debbie Saslow; Worta McCaskill-Stevens; Stuart J Schnitt
Journal:  CA Cancer J Clin       Date:  2012-04-04       Impact factor: 508.702

2.  Progression of Ductal Carcinoma in Situ from the Pathological Perspective.

Authors:  Pedro Oscar R Cunha; Mark Ornstein; J Louise Jones
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

3.  Why I became a surgical pathologist with interest in breast disease.

Authors:  David L Page
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

Review 4.  Folate, DNA methylation, and mouse models of breast tumorigenesis.

Authors:  Joshua W Miller; Alexander D Borowsky; Teresa C Marple; Erik T McGoldrick; Lisa Dillard-Telm; Lawrence J T Young; Ralph Green
Journal:  Nutr Rev       Date:  2008-08       Impact factor: 7.110

5.  Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.

Authors:  Amy Brock; Silva Krause; Hu Li; Marek Kowalski; Michael S Goldberg; James J Collins; Donald E Ingber
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

Review 6.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

7.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

8.  Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

Authors:  Nicolien T van Ravesteyn; Jeroen J van den Broek; Xiaoxue Li; Harald Weedon-Fekjær; Clyde B Schechter; Oguzhan Alagoz; Xuelin Huang; Donald L Weaver; Elizabeth S Burnside; Rinaa S Punglia; Harry J de Koning; Sandra J Lee
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

9.  Risk stratification of ductal carcinoma in situ using whole-lesion histogram analysis of the apparent diffusion coefficient.

Authors:  Jin You Kim; Jin Joo Kim; Ji Won Lee; Nam Kyung Lee; Geewon Lee; Taewoo Kang; Heesung Park; Yo Han Son; Robert Grimm
Journal:  Eur Radiol       Date:  2018-08-02       Impact factor: 5.315

10.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.